Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?